Case Studies - Pre-Clinical Development
Viriom, Russia and Hoffman La Roche Ltd., Switzerland, signed a collaboration agreement for research and development of innovative medicines for HIV, and ChemDiv was chosen by Viriom as a strategic partner to carry out pre-clinical and clinical development of this program.
Due to changes in corporate strategy, Roche was looking for a partner to take over its internal HIV program and had a couple of very promising compounds in the pipeline that showed good potential to become best-in-class drugs. ChemDiv stepped forward with an innovative solution for Roche and proposed to form a partnership and consolidate Roche’s HIV assets in a start up biotech company Viriom to be able to move forward the compounds. ChemDiv offered its services and expertise in preclinical research and clinical development to help advance the program in the most time- and cost-efficient way.
In a press statement, Vadim Bichko, ChemDiv’s VP of Virology, noted: “These HIV inhibitors have shown excellent antiviral properties in vitro, good bioavailability, PK and safety profiles, as well as a high genetic barrier to resistance.”
In this one-of-a- kind deal, Roche made a bold decision, which helped the company advance the innovative HIV program with an experienced and reliable partner and at a fraction of the costs typically associated with such development. For Roche, it also opened new opportunities as well as strategic access to the emerging Russian pharmaceutical market.
Products & Services